Best of iHub

[NASDAQ2020]

2 year play
ELTP

X 1. Cash Flow Positive Status - 5 years
X 2. Purchase main building housing their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million Approved and Launched
X 4. Adderall XR $1.56 Billion Approved and Launched
X 5. Double digit quarterly revenues in millions
X 6. In house marketing and distribution: Kirkov
X 7. Prasco/Burel Adderall agreement starting January 1st 2024
X 8. First shipment Adderall XR to PRASCO Dec 2023
X 9. DEA increases manufacturing quotas for Adderall & Vyvance
X 10. Generic Vyvanse - $5.1 BILLION - FDA submission Dec 2023
X 11. FDA Acceptance of Generic OxyContin Sept 2023
__12. $50 million in yearly revenues
__13. Generate revenues over $20 million/quarter
__14. Generic OxyContin Approval -;FIRST TO FILE Aug 17, 2023 $720 Million
__15. Prevail over Purdue in Generic OxyContin infringement suit - 6 month stay
X 16. Lease additional manufacturing space and storage vault for new Needle Mover ANDAs Jan 2024
__17. European distribution - Dexcel partnership approval by Israeli Health
__18. Full ownership of Adderall IR $ 335 Million
__19. Full ownership of Adderall XR $ 1.56 Billion
__20. Generic Concerta- $1.2 BILLION FDA submission
__21. Vigabatrin - VigPoder approved Pyros $233 Million trade mark challenge
__22. $100 million in yearly revenues
__23. Dopamine Agonist (probably Requip XL or Mirapex ER). $12 Million
__24. Patented Unique ADF (w/o naltrexone)-- NDA
__25. Mikah ANDA (s)
__26. Undisclosed ANDAs/NDAs
__27. Antimetabolite ANDA- Methotrexate -$600 Million - unconfirmed
__28. Undisclosed Antimetabolite ANDA- $42 Million
__29. Generic Vyvanse Approval
__30. DollarLand PPS
__31. Uplist to the NASDAQ Exchange
__32. ELTP Elite Pharmaceutical Buyout - less than 2 1/2 years from Feb 2024
__33. Vegas Baby !!!!!!!

What would Mr. Hakim say is the likelihood that Elite will get bought out by a large rival within the next five years?

Two things I'll say to that. One, cut that prediction in half or more than half. Five years is a very long time to do either. We are at a point where our fundamentals are solid, and we are in a growth stage, as I said earlier. We're not flattening out at $30 million and $40 million. We skip the 40s, went to 50s. And we'll talk in June once I have a little more data, what I expect for the future. But definitely, the year after, we're going to beat that. And the year after, we're going to be that.

So we're at a growth stage. So the fundamentals are looking great, a buyout is looking great. And five years is way too long for that. So I would say either of this will happen in a couple of years.